2025-07-28 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, presented in an English report format with numbers, analysis, and tables.

## Johnson & Johnson (JNJ) Stock Analysis

**Company Overview:** Johnson & Johnson (JNJ) is a global healthcare company that develops, manufactures, and sells pharmaceuticals, medical devices, and consumer health products.

### 1. Relative Performance

*   **Ticker:** JNJ
*   **Cumulative Return (JNJ):** 23.98%
*   **Cumulative Return (S&P 500 / VOO):** 99.66%
*   **Performance Spread (JNJ - VOO):** -74.0%
*   **Relative Spread Percentile:** 8.7% (Indicates JNJ's relative performance is near the bottom 8.7% of its historical range compared to the S&P 500)

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) based on the provided cumulative returns. The Relative Spread Percentile of 8.7% suggests that this underperformance is relatively significant compared to its historical trends.

**Alpha and Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha   | Beta   | Cap (B) |
|------------|----------|----------|---------|--------|---------|
| 2015-2017  | 28.0%   | 56.1%    | -1.0%   | -0.0   | 336.5   |
| 2016-2018  | 8.0%    | 56.6%    | -10.0%  | 0.0    | 310.8   |
| 2017-2019  | 18.0%   | 56.6%    | -12.0%  | 0.7    | 351.3   |
| 2018-2020  | 12.0%   | 59.2%    | -8.0%   | 0.3    | 379.0   |
| 2019-2021  | 32.0%   | 59.6%    | -16.0%  | 0.2    | 412.0   |
| 2020-2022  | 7.0%    | 61.4%    | 5.0%    | 0.2    | 425.4   |
| 2021-2023  | -15.0%  | 61.4%    | -33.0%  | 0.4    | 377.5   |
| 2022-2024  | -35.0%  | 61.4%    | -61.0%  | 0.3    | 348.3   |
| 2023-2025  | -3.0%   | 70.1%    | -55.0%  | 0.2    | 405.3   |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate shows fluctuating performance, with negative growth in recent periods (2021-2025).
*   **MDD:** Maximum Drawdown is consistently high, indicating significant potential losses from peak to trough.
*   **Alpha:**  Alpha is largely negative, suggesting underperformance relative to its benchmark, particularly worsening in recent years.
*   **Beta:** Beta values are low, indicating JNJ is less volatile than the market.
*   **Cap:** Market Capitalization has varied over time, suggesting evolving investor sentiment and market conditions.

### 2. Recent Price Action

*   **Current Price:** \$168.30
*   **Last Market Data:**
    *   Price: \$168.30
    *   Previous Close: \$169.56
    *   Change: -\$0.74
*   **5-Day Moving Average:** \$167.85
*   **20-Day Moving Average:** \$159.87
*   **60-Day Moving Average:** \$155.64

**Analysis:** The stock price has experienced a slight decrease compared to the previous close. The 5-day moving average is above the 20-day and 60-day moving averages, suggesting a short-term upward trend.

### 3. Technical Indicators and Outlook

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 76.93 (Overbought)
*   **PPO:** 0.707
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent Relative Divergence (20-day):** +2.6 (Short-term Increase)
*   **Expected Return:** -316.4%

**Analysis:**

*   The MRI indicates a "Low Risk" market environment.
*   The RSI is in overbought territory, suggesting the stock price may be due for a correction.
*   The Hybrid Signal recommends buying with caution, aligning with the MRI indicating low market risk but tempering this recommendation due to other factors.
*   The positive recent relative divergence suggests a short-term upward momentum, although caution is warranted considering the overbought RSI.
*   The significantly negative Expected Return suggests long-term underperformance compared to the S\&P 500 if investing at the current price.

### 4. Recent News & Events

*   **2025-07-25:** Major business developments, regulatory changes, or market events.
*   **2025-07-28:** Analyst discussions regarding performance and outlook.
*   **2025-07-26:** Stock volatility influenced by recent news, earnings, or executive actions.
*   **2025-07-27:** Market experts highlight both risks and opportunities.

**Analysis:** Recent news suggests that JNJ has been subject to significant market activity and events, indicating the need for investors to stay informed about the latest developments.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-07-24 | 2.30 | 23.74 B\$ |
| 2025-04-23 | 4.57 | 21.89 B\$ |
| 2024-10-23 | 1.12 | 22.47 B\$ |
| 2024-07-25 | 1.95 | 22.45 B\$ |
| 2025-07-24 | 1.95 | 22.45 B\$ |

**Analysis:** The EPS and revenue data show fluctuations over the reported quarters. The latest quarter (2025-07-24) indicates solid revenue with a moderate EPS. However, the EPS varies significantly across the quarters, which might require further investigation into the specific factors affecting profitability.

### 6. Financial Information

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | \$23.74B  | 67.87%        |
| 2025-03-31   | \$21.89B  | 66.40%        |
| 2024-12-31   | \$22.52B  | 68.35%        |
| 2024-09-30   | \$22.47B  | 69.01%        |
| 2024-06-30   | \$22.45B  | 69.40%        |

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-06-30   | \$78.47B  | 7.06%     |
| 2025-03-31   | \$78.11B  | 14.08%    |
| 2024-12-31   | \$71.49B  | 4.80%     |
| 2024-09-30   | \$70.16B  | 3.84%     |
| 2024-06-30   | \$71.54B  | 6.55%     |

**Analysis:**

*   **Revenue and Profitability:** The revenue has been relatively stable, with profit margins consistently high (above 66%).
*   **Capital and Profitability:** Equity has generally increased. ROE has fluctuated, with a significant spike in 2025-03-31.

### 7. Overall Analysis

Johnson & Johnson (JNJ) presents a mixed picture. While the company maintains high profit margins and consistent revenue, it has significantly underperformed the S\&P 500 based on cumulative returns. The negative expected return suggests a long-term investment might not yield favorable results compared to the benchmark. The overbought RSI indicates a potential short-term correction, despite the low-risk market environment indicated by the MRI. Recent news and analyst discussions suggest the stock has been subject to volatility and significant market events, requiring careful monitoring. The recent earnings show mixed results, with varying EPS and stable revenue.
